Verification evidence is still being completed.
PDF / print export
GE HealthCare Lindesnes
Lindesnes, Norway
- Verified lead
- Peter J. Arduini
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- President and CEO, GE HealthCare Technologies (global)
- 2026 technical specialization
- API Manufacturing, Iodinated Contrast Media, and Global Pharma Supply Chain
- Review cycle
- 24 April 2026
- Full address
- Lindesnesveien 208, 4521 Lindesnes (Spangereid), Norway
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- GE HealthCare investor release covering the Lindesnes API facility expansion.
- Editorial note
- Norway's largest pharma site with approximately 450 staff, GMP and FDA-inspected API manufacturing for iohexol and iodixanol, and a disclosed 80 million USD 2022 capacity expansion.
API Manufacturing, Iodinated Contrast Media, and Global Pharma Supply Chain
GMP API manufacturing, FDA inspection for US supply, Public investor disclosure of site expansion
Norway's largest pharma site with approximately 450 staff, GMP and FDA-inspected API manufacturing for iohexol and iodixanol, and a disclosed 80 million USD 2022 capacity expansion.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lindesnes, Norway
GE HealthCare Lindesnes
API Manufacturing, Iodinated Contrast Media, and Global Pharma Supply Chain · Bulk API manufacturing for global contrast-media supply
Norway's largest pharma site with approximately 450 staff, GMP and FDA-inspected API manufacturing for iohexol and iodixanol, and a disclosed 80 million USD 2022 capacity expansion.
- Lead
- Peter J. Arduini (verified ↗)
- Address
- Lindesnesveien 208, 4521 Lindesnes (Spangereid), Norway (source ↗)
- Compliance
- GMP API manufacturing · FDA inspection for US supply
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Bulk API manufacturing for global contrast-media supply
- Capabilities
- Iodine-to-API Chemical Synthesis · Iohexol and Iodixanol API Production · Integrated 100-Acre Chemical Campus
- Founded
- 2023
- Headcount
- 10000+
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Peter J. Arduini
President and CEO, GE HealthCare Technologies (global)
Full addressLindesnesveien 208, 4521 Lindesnes (Spangereid), Norway
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Panjiva shipping record for GE Healthcare AS listing the Lindesnesveien address in Lindesnes.
Open sourceBulk API manufacturing for global contrast-media supply
Lindesnes, Norway. API Manufacturing, Iodinated Contrast Media, and Global Pharma Supply Chain. Review completed on 24 Apr 2026.
Norwegian Medicines Agency and FDA for US supply
GMP API manufacturing, FDA inspection for US supply, Public investor disclosure of site expansion
API Manufacturing, Iodinated Contrast Media, and Global Pharma Supply Chain
Norway's largest pharma site with approximately 450 staff, GMP and FDA-inspected API manufacturing for iohexol and iodixanol, and a disclosed 80 million USD 2022 capacity expansion.
Editorial note
GE HealthCare Lindesnes is Norway's largest pharma site with approximately 450 staff, documented GMP API manufacturing for iohexol and iodixanol, and a disclosed 80 million USD 2022 capacity expansion supporting global contrast-media supply.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Iodine-to-API Chemical Synthesis
Iohexol and Iodixanol API Production
Integrated 100-Acre Chemical Campus
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Chemical synthesis trains
API purification and packaging
Quality-control laboratories
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- VERIFIED ACTIVE 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is GE HealthCare Lindesnes located?
- GE HealthCare Lindesnes operates from Lindesnesveien 208, 4521 Lindesnes (Spangereid), Norway, Lindesnes, Norway.
- Who runs GE HealthCare Lindesnes?
- GE HealthCare Lindesnes is led by Peter J. Arduini, President and CEO, GE HealthCare Technologies (global). Verified 24 Apr 2026.
- What certifications does GE HealthCare Lindesnes hold?
- GE HealthCare Lindesnes is documented under GMP API manufacturing, FDA inspection for US supply.
- What does GE HealthCare Lindesnes do?
- Norway's largest pharma site with approximately 450 staff, GMP and FDA-inspected API manufacturing for iohexol and iodixanol, and a disclosed 80 million USD 2022 capacity expansion. Core capabilities: Iodine-to-API Chemical Synthesis, Iohexol and Iodixanol API Production, Integrated 100-Acre Chemical Campus.
Editorial context
Related technical briefs
Briefs that name Lindesnes as a covered market or city.